All the news Showing 10 of 23 articles from: AASLD 2013Get an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Protease inhibitors Faldaprevir safe and effective in HCV treatment-experienced patients Michael Carter / 13 December 2013 Triple therapy including the investigational hepatitis C virus (HCV) protease inhibitor faldaprevir is a safe and effective treatment for people who did not respond to a previous course of HCV treatment, results of ... Therapies Liver Meeting ends with hepatitis C debrief and the future of treatment Keith Alcorn / 11 December 2013 The final day of The Liver Meeting 2013, the 64th annual meeting of the American Association for the Study of Liver Diseases (AASLD) recently held in Washington, DC, featured an overview of ... Tenofovir alafenamide shows similar anti-hepatitis B activity with less kidney toxicity Liz Highleyman / 05 December 2013 A new formulation of tenofovir that can be taken at lower doses demonstrated potent activity against hepatitis B virus (HBV) similar to that of the existing formulation in a 28-day study, but ... Black hepatitis C patients do well on sofosbuvir oral regimens Liz Highleyman / 03 December 2013 Interferon-free treatment using a single once-daily combination pill containing sofosbuvir plus ledipasvir demonstrated potent activity against hepatitis C virus (HCV) and was generally well tolerated in a primarily African-American inner city population with ... Interferon-free regimens Faldaprevir all-oral regimen shows 100% response rate for people with HCV 1a in interim analysis Liz Highleyman / 02 December 2013 An interferon-free regimen of faldaprevir, deleobuvir and PPI-668 led to a 4-week post-treatment sustained virological response (SVR4) in treatment-naive patients with hard-to-treat HCV subtype 1a in an ongoing phase 2 trial, according to ... Antiviral therapy Entecavir + tenofovir works well for people with hepatitis B who have had prior treatment failure Liz Highleyman / 28 November 2013 A dual regimen of entecavir (Baraclude) plus tenofovir (Viread) for 48 weeks led to virological response and was generally well-tolerated among people with chronic hepatitis B who had experienced treatment failure with ... Interferon-free regimens Daclatasvir + asunaprevir cures 85% of genotype 1b hepatitis C patients in Japanese study Liz Highleyman / 27 November 2013 An interferon- and ribavirin-free oral regimen of daclatasvir plus asunaprevir taken for 24 weeks led to sustained virological response (SVR12) in 85% of Japanese patients with hepatitis C virus subtype 1b, according to ... HBV vaccination Hepatitis B vaccine protection lasts for at least 30 years Liz Highleyman / 21 November 2013 Hepatitis B vaccination provides long-term protection through 30 years for a majority of recipients, and more than 90% were protected with either initial immunisation or a booster, according to a presentation at ... Treatment outcomes Successful hepatitis C treatment reduces risk of liver cancer and death, but most remain untreated Liz Highleyman / 19 November 2013 Hepatitis C treatment that leads to viral cure significantly reduces the likelihood of liver disease progression and liver-related mortality, but most people with hepatitis C remain untreated, according to a presentation at The Liver ... Nucleotide Ns5B polymerase inhibitors Sofosbuvir/ribavirin for 24 weeks cures most genotype 3 hepatitis C patients, adding interferon may help difficult-to-treat Liz Highleyman / 14 November 2013 A dual oral regimen of sofosbuvir plus ribavirin led to sustained response for 93% of people with genotype 2 hepatitis C treated for 12 weeks and 85% of people with genotype 3 ... ← First123Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive